|
Patient ID
|
No. of Vaccinations
|
Antigens (Type of Lysate)
|
Median No. of Administered Cells × 106(range)
|
DTH Best Response after 4 or More Vaccinations.
|
Vitiligo
|
Clinical Response
|
Response Duration (Months)
|
Overall Survival (Months)
|
|---|
| | | | |
L/H
|
KLH
| | | | |
|---|
|
1 L.A.
|
8
|
H
|
49.5 (15 – 82)
|
+
|
+
| |
SD
|
6
|
45
|
|
2 G.I.
|
5
|
L
|
13 (4.5 – 26)
|
-
|
+
| |
SD
|
6
|
26
|
|
3 M.G.
|
5
|
L
|
11 (7 – 16.2)
|
-
|
-
|
+/-
|
SD
|
6
|
7
|
|
4 S.P.
|
8
|
L
|
26.5 (10 – 43.5)
|
-
|
-
| |
PD
|
-
|
8
|
|
5 G.C.
|
6
|
L
|
19 (9.6 – 32)
|
-
|
-
| |
PD
|
-
|
10
|
|
6 Z.V.
|
5
|
L/H
|
11.3 (6.4 – 21.5)
|
-
|
-
| |
PD
|
-
|
4
|
|
7 G.L.
|
6
|
H
|
22.6 (16.4 – 48)
|
-
|
-
| |
PD
|
-
|
5
|
|
8 B.A.
|
4
|
H
|
15 (12 – 51)
|
-
|
-
| |
PD
|
-
|
5
|
|
No. of Patients
|
Administration Route
|
Site
|
No. of Inoculations
| | | | | | |
|
8 iDC
|
4 i.d. and 4 s.c.
|
6 inguinal and 2 axillary
|
6–8
| | | | | | |
- DTH, delayed-type hypersensitivity; L, autologus lysate; H, autologous homogenate; KLH, keyhole limpet hemocyanin; SD, stabilization; PD, progressive disease.
- i.d., intradermal; s.c., subcutaneous
